4.8 Article

slan+ thorn Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP

期刊

CANCER RESEARCH
卷 78, 期 13, 页码 3544-3559

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-17-2344

关键词

-

类别

资金

  1. Associazione Italiana per la Ricerca sul Cancro - Italy (AIRC) [IG-15454, IG-15378]
  2. University of Verona (Ricerca di Base)
  3. Fondazione Umberto Veronesi
  4. Fondazione Italiana per la Ricerca sul Cancro
  5. Fondazione Beretta (Brescia, Italy)

向作者/读者索取更多资源

Terminal tissue differentiation and function of slan(+) monocytes in cancer is largely unexplored. Our recent studies demonstrated that slan(+) monocytes differentiate into a distinct subset of dendritic cells (DC) in human tonsils and that slan(+) cells colonize metastatic carcinoma-draining lymph nodes. Herein, we report by retrospective analysis of multi-institutional cohorts that slan(+) cells infiltrate various types of non-Hodgkin lymphomas (NHL), particularly the diffuse large B-cell lymphoma (DLBCL) group, including the most aggressive, nodal and extranodal, forms. Nodal slan(+) cells displayed features of either immature DC or macrophages, in the latter case ingesting tumor cells and apoptotic bodies. We also found in patients with DLBCL that peripheral blood slan(+) monocytes, but not CD14(+) monocytes, increased in number and displayed highly efficient rituximab-mediated antibody-dependent cellular cytotoxicity, almost equivalent to that exerted by NK cells. Notably, slan(+) monocytes cultured in conditioned medium from nodal DLBCL (DCM) acquired a macrophage-like phenotype, retained CD16 expression, and became very efficient in rituximab-mediated antibody-dependent cellular phagocytosis (ADCP). Macrophages derived from DCM-treated CD14(+) monocytes performed very efficient rituximab-mediated ADCP, however, using different Fc gamma Rs from those used by slan(+) macrophages. Our observations shed new light on the complexity of the immune microenvironment of DLBCL and demonstrate plasticity of slan(+) monocytes homing to cancer tissues. Altogether, data identify slan(+) monocytes and macrophages as prominent effectors of antibody-mediated tumor cell targeting in patients with DLBCL. Significance: slan(+) monocytes differentiate into macrophages that function as prominent effectors of antibody-mediated tumor cell targeting in lymphoma. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3544/F1.large.jpg. (C) 2018 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据